Comparative Pharmacology
Head-to-head clinical analysis: MINASTRIN 24 FE versus NORTREL 1 35 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MINASTRIN 24 FE versus NORTREL 1 35 21.
MINASTRIN 24 FE vs NORTREL 1/35-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an estrogen (ethinyl estradiol) and a progestin (norethindrone acetate) that inhibits gonadotropin release from the pituitary, suppressing ovulation, thickening cervical mucus, and altering endometrial receptivity.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, altering cervical mucus to impede sperm penetration, and inducing endometrial changes that reduce implantation likelihood.
One tablet orally once daily for 24 weeks, followed by 4 placebo tablets. Each tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol for 21 days, then 1 mg norethindrone acetate and 0.75 mg ferrous fumarate for 7 days.
One tablet orally once daily for 21 days, followed by 7 days off, then repeat.
None Documented
None Documented
Norethindrone: 7-8 hours; ethinyl estradiol: 13-27 hours. Clinical context: Steady-state achieved within 5-10 days; half-life supports once-daily dosing.
Norethindrone: 5-14 hours; Ethinyl estradiol: 17-24 hours. Steady-state achieved after 10 days.
Urine (primarily as glucuronide conjugates; ethinyl estradiol and norethindrone metabolites) and feces. Approximately 40% of norethindrone metabolites are excreted in urine and 60% in feces. Ethinyl estradiol is excreted as glucuronide and sulfate conjugates in urine (40%) and feces (60%).
Renal 50-60% as metabolites, fecal 40-50% as conjugates, <1% unchanged
Category C
Category C
Oral Contraceptive
Oral Contraceptive